9-(2-Phosphonylmethoxyethyl)adenine (PMEA) belongs to a new class of nucleotide analogs with strong and selective activity against a wide range of viruses, including retroviruses (i.e., human immunodeficiency virus types 1 and 2 [HIV-1 and HIV-2]) (30) , herpesviruses (i.e., herpes simplex virus types 1 and 2, varicella zoster virus, human cytomegalovirus, and Epstein-Barr virus) (11) , and hepadnaviruses (i.e., hepatitis B virus) (39) . The antiviral potential of PMEA has been demonstrated in numerous in vitro and in vivo experiments (4, 5, 12-16, 20, 21, 35, 36) and has recently been reviewed (27) . PMEA has entered phase I/II trials in HIV-infected individuals, and the initial clinical data appear to be encouraging (8, 38) . The antiviral activity of PMEA is generally ascribed to its diphosphorylated metabolite, designated PMEApp, which has been shown to inhibit the viral DNA polymerase of herpesviruses and the reverse transcriptase of retroviruses (2, 19, 37) . As yet, it is unclear which enzymes are involved in the intracellular conversion of PMEA to PMEApp (1, 7, 22) . Because of the phosphonate group, PMEA can circumvent the first phosphorylation step that is essential for the activation of nucleoside analogs such as zidovudine (3Ј-azido-3Ј-deoxythymidine [AZT]), zalcitabine (ddC), didanosine (ddI), and stavudine (2Ј,3Ј-didehydro-3Ј-deoxythymidine [D4T]). However, the high anionic charge of the phosphonate moiety of PMEA is held responsible for the rather low cellular uptake of PMEA (29) . In addition, PMEA has been shown to have low oral bioavailability, i.e., 7.8% in rats and 4.0% in cynomolgus monkeys (10, 31) . Hence, PMEA needs to be injected, which is a major obstacle for long-term clinical application. From a large number of newly synthesized lipophilic esters of PMEA, the bis(pivaloyloxymethyl) [bis(POM)] ester prodrug was selected as a potentially useful prodrug of PMEA (34) . Indeed, the oral bioavailabilities of bis(POM)-PMEA have been reported to be 17.6 and 25% in rats and cynomolgus monkeys, respectively (9, 34) . We have investigated the antiviral efficacy of bis(POM)-PMEA upon oral administration in retrovirus-infected mice. Oral bis(POM)-PMEA proved to be as efficacious as subcutaneous PMEA given at an equimolar dose. In addition, we performed pharmacokinetic studies with mice to determine the efficiency with which oral bis(POM)-PMEA is absorbed and converted to free PMEA.
MATERIALS AND METHODS
Animals. Female NMRI mice were purchased from Charles River Deutschland, Sulzfeld, Germany. Severe combined immune deficiency (SCID) mice were bred at the Rega Institute under germ-free conditions; during the experi-ments, they were housed under specific-pathogen-free conditions. Male and female SCID mice were used at random. Antiviral studies were performed with animals that were provided with food and acidified water ad libitum. For the kinetic experiments, mice were fasted from 15 h before until the end of the study.
Drugs. PMEA, bis(POM)-PMEA, and diphenyl-PMEA ( Fig. 1) were synthesized at Gilead Sciences, Inc., Foster City, Calif. The compounds were administered by oral gavage (0.5 ml per mouse) or by intravenous or subcutaneous injection (0.2 ml per mouse). Oral solutions of PMEA were prepared in distilled water; for subcutaneous or intravenous injection, PMEA was dissolved in isotonic phosphate buffer. All solutions of PMEA were neutralized to pH 7 with 2 N sodium hydroxide. For oral administration of bis(POM)-PMEA or diphenyl-PMEA, the compounds were dissolved in 100% absolute ethanol, divided into aliquots, and kept at Ϫ20ЊC. Prior to administration, an aliquot of the ethanol solution was diluted 10-fold with distilled water. These oral formulations contained Ͻ10% monoester and 0% PMEA, as determined by high-performance liquid chromatography (HPLC) analysis.
Viruses. Moloney murine sarcoma virus (MSV) stocks were prepared from tumors induced in 3-day-old NMRI mice. Stocks of Friend leukemia virus complex (FLV) (kindly provided by B. Rosenwirth, Sandoz Forschungsinstitut, Vienna, Austria, and originally obtained from American Type Culture Collection [no. 245]) were made up from the spleens of FLV-infected NMRI mice.
In vitro assays. Antiviral assays for HIV-1 and HIV-2 were performed with human CEM T4-lymphocyte cells, according to previously described procedures (4) . The anti-MSV activities of the compounds were measured by a transformation assay with MSV-infected murine C3H/3T3 fibroblast cells (4) .
MSV infection of SCID mice. On day 0, MSV was inoculated intramuscularly in the left hind legs of 3-week-old SCID mice. Oral or subcutaneous drug treatment was performed twice daily, on days 0 through 4. Development of MSV-induced tumors and associated death was monitored daily. On days 5, 7, and 10 postinfection (p.i.), tumor sizes were measured with calipers.
FLV infection of NMRI mice. Female NMRI mice (weighing Ϸ15 g) were inoculated with FLV by intravenous injection via the tail vein. Drugs were administered twice daily on days 0 through 4. At day 14 p.i., the mice were dissected, and the spleens were removed and weighed. The efficacy of antiviral drug treatment was expressed as the percent inhibition of FLV-induced splenomegaly, according to the following formula: % inhibition of splenomegaly ϭ {(1Ϫ(xϪz)/(yϪz)] ⅐ 100%}, in which x is the mean spleen weight of drug-treated mice, y is the mean spleen weight of untreated infected mice, and z is the mean spleen weight of untreated uninfected mice.
Detection of PMEA in plasma and urine. All pharmacokinetic studies were performed with female NMRI mice (body weight, 20 to 25 g). The disposition of PMEA was determined from the concentrations of free PMEA in plasma following intravenous bolus injection of PMEA or oral gavage of bis(POM)-PMEA, diphenyl-PMEA, or PMEA (all doses, 50 mg of PMEA equivalent per kg of body weight). At different times after administration (i.e., at 2, 5, 10, 20, 30, 60, 90, 120, 180, 240, and 480 min), the mice were anesthetized with diethyl ether, and blood was drawn by cardiac puncture and collected in heparinized tubes (one mouse per time point). The blood samples were immediately put on ice and centrifuged (12,000 ϫ g, 3 min). Plasma was collected and frozen at Ϫ20ЊC until analyzed. The methods for extraction, HPLC analysis, and fluorescence detection of PMEA in the plasma have been described previously (25) . Briefly, plasma proteins were removed by treatment with ice-cold trichloroacetic acid followed by high-speed centrifugation. After neutralization, plasma extracts were treated with ammonium acetate buffer (pH 4.7) and chloroacetaldehyde. Conversion of PMEA into its fluorescent 1,N 6 -etheno-adenine derivative was accomplished by 20 min of heating at 95ЊC. Standards were prepared from blank plasma samples, which were spiked with known amounts of PMEA and extracted on-line with the unknown plasma samples. The extracts were separated by ion-pairing reversedphase HPLC, using a C 8 column from Merck (Lichrospher 60 RP-Select B; particle size, 5 m; column dimensions, 125 by 4 mm) and a gradient system consisting of buffer A (2.5 mM dihydrogen ammonium phosphate-2 mM tetrabutylammonium hydrogen sulfate mixed with 5% acetonitrile) and buffer B (75 mM dihydrogen ammonium phosphate-2 mM tetrabutylammonium hydrogen sulfate mixed with 15% acetonitrile) (both buffers at pH 5.0) (25) . An HPLC System Two from Pharmacia LKB (Uppsala, Sweden) was used, supplemented with a Waters (Milford, Mass.) model 420 fluorescence detector equipped with a mercury lamp. Appropriate filters were installed for excitation at 254 nm and emission at 425 nm. The fluorescence assay for detection of PMEA in plasma was highly sensitive (detection limit, 0.05 g of PMEA per ml of plasma) and reliable, with a linearity between 1 and Ͼ1,000 g/ml, an interassay variation of 2 to 14%, and an intra-assay variation of 4 to 10% (25) . Also, it was ensured that the parent prodrugs [bis(POM)-PMEA and diphenyl-PMEA] that may have been present in the plasma samples were not converted to PMEA during derivatization with chloroacetaldehyde. However, this derivatization resulted in degradation of bis(POM)-PMEA to mono(POM)-PMEA and of diphenyl-PMEA to monophenyl-PMEA, for about 50 and 20%, respectively. Therefore, plasma analysis of bis(POM)-PMEA and diphenyl-PMEA and the corresponding monoester metabolites [mono(POM)-PMEA and monophenyl-PMEA] could be performed only by classical UV detection. In addition, in these analyses, plasma samples were deproteinized with methanol to prevent breakdown by trichloroacetic acid used in the fluorescence assay for PMEA.
In another set of experiments, PMEA in the urine of mice that received an intravenous bolus injection of PMEA or an oral gavage of bis(POM)-PMEA, diphenyl-PMEA, or PMEA was determined. All compounds were administered at doses equivalent to 25 or 100 mg of PMEA per kg. The animals were placed immediately in metabolic cages (two mice per cage), and urine was collected at 24 h after administration of the compounds. The urine samples were centrifuged to remove food and fecal debris and frozen. After addition of ammonium acetate buffer and chloroacetaldehyde and 20 min of heating at 95ЊC, the urine extracts were analyzed by HPLC as described above.
Pharmacokinetic calculations. Pharmacokinetic parameters were calculated for each individual experiment and averaged. The elimination half-life (t 1/2 ) of PMEA upon intravenous bolus injection was calculated from monoexponential equations, using the formula t 1/2 ϭ 0.693/k el , in which k el equals the elimination rate constant, derived from the slope of the linearized elimination curve that was obtained by least-squares regression analysis of the semilogarithmic plasma drug concentration-time curve. The linear trapezoidal rule was used to calculate the area under the curve values (AUCs) for free PMEA. Total body clearance (CL t ) was computed from the formula CL t ϭ dose/AUC. The oral bioavailability of PMEA following oral administration of PMEA, bis(POM)-PMEA, or diphenyl-PMEA was calculated from the ratio AUC p.o., 0-8 /AUC i.v., 0-8 , in which AUC p.o., 0-8 equals the AUC for PMEA from 0 to 8 h upon oral gavage of PMEA or its ester prodrug and AUC i.v., 0-8 equals the AUC for PMEA from 0 to 8 h upon intravenous bolus injection of PMEA at an equivalent dose. The urinary recovery of PMEA was defined as the ratio of the amount of free PMEA collected in the urine to the total amount of PMEA equivalent administered.
RESULTS
Antiretroviral activity in vitro. PMEA, bis(POM)-PMEA, and diphenyl-PMEA were evaluated for their inhibitory effects on HIV-1 and HIV-2 replication in human T4-lymphocyte CEM cells and on MSV-induced transformation of murine C3H/3T3 fibroblast cells (Table 1) . Bis(POM)-PMEA was 20-to 30-fold superior to PMEA in inhibiting HIV-1 and HIV-2 replication in CEM cells, and its inhibitory effect on MSV was 250 times more pronounced than that of PMEA. Diphenyl-PMEA was two-to sixfold more potent than PMEA as an inhibitor of HIV-1 and HIV-2 replication but proved no more effective than PMEA in inhibiting MSV. Bis(POM)-PMEA was markedly more cytotoxic to CEM cells than PMEA and diphenyl-PMEA. Consequently, for CEM cells, the selectivity index (ratio of the concentration producing 50% inhibition of cell viability to the concentration producing 50% inhibition of virus-induced cytopathicity) of bis(POM)-PMEA was comparable to that of PMEA and diphenyl-PMEA. However, for C3H/3T3 murine fibroblast cells, the selectivity index VOL. 40, 1996 ACTIVITY AND PHARMACOKINETICS OF BIS(POM)- PMEA 23 of bis(POM)-PMEA was clearly superior to that of PMEA (Table 1) . Protective effect against MSV infection in mice. The antiviral compounds were evaluated for their potential in delaying MSV-induced tumor appearance and associated death in MSV-infected SCID mice (Table 2 ). Untreated control mice developed massive tumors at the site of MSV injection, with a mean time of tumor appearance of 4.8 days. These mice eventually died within 14 days p.i. PMEA administered subcutaneously for 5 days at a dose of 20, 50, or 100 mg/kg/day effected a significant delay in MSV-induced tumor development and associated death. Oral treatment with PMEA at a daily dose of 50 or 100 mg/kg proved only marginally effective, the mean time of tumor appearance being 6.3 days (P Ͻ 0.1). In contrast, a marked anti-MSV effect was noted for bis(POM)-PMEA when administered orally at a dose of 50 or 100 mg of PMEA equivalent per kg per day (mean times of tumor appearance, 8.1 and 9.8 days, respectively; P Ͻ 0.0025 versus control). Furthermore, oral bis(POM)-PMEA exerted the same antiviral effect as subcutaneous PMEA given at an equimolar dose. For instance, at a dosage of 100 mg of PMEA equivalent per kg per day, oral bis(POM)-PMEA and subcutaneous PMEA achieved a twofold increase in the mean day of tumor appearance [from 4.8 days for untreated control mice to 9.8 and 10.0 days for the mice treated with oral bis(POM)-PMEA or subcutaneous PMEA, respectively; P Ͼ 0.25 for comparison of oral bis(POM)-PMEA and subcutaneous PMEA]. The two drug regimens also proved to be not significantly different at the dosage of 50 mg of PMEA equivalent per kg per day (P Ͼ 0.25). Oral diphenyl-PMEA at a dosage of 100 mg of PMEA equivalent per kg per day executed a rather weak antiviral response (mean time of tumor appearance, 7.6 days; P Ͻ 0.025 for comparison with untreated control), and its efficacy was significantly lower than that of an equivalent dose of subcutaneous PMEA (P Ͻ 0.0005 for comparison of the two drug regimens). In addition, MSV-induced tumors were measured at days 5, 7, and 10 p.i. (Fig. 2) . Initially, mice receiving oral bis(POM)-PMEA or subcutaneous PMEA had markedly smaller MSV tumors than control mice. However, whatever the antiviral treatment, all the tumors finally attained the same size, and eventually, all the MSV-infected mice died.
Protective effect against FLV infection. FLV-infected NMRI mice were treated with PMEA, bis(POM)-PMEA, or diphenyl-PMEA, according to the same dosage regimens used in the MSV studies. FLV infection resulted in a marked splenomegaly at day 14 p.i. (mean spleen weight of FLV-infected mice, 0.93 g, compared with 0.11 g for uninfected mice) ( Table 3) . Oral bis(POM)-PMEA and subcutaneous PMEA afforded considerable and similar antiretroviral responses, with Ͼ80% inhibition of FLV-induced splenomegaly at a dosage of 100 mg of PMEA equivalent per kg per day (P Ͼ 0.25 for comparison of the two drug regimens). Oral therapy with PMEA or diphenyl-PMEA was less efficient.
Pharmacokinetics in mice. Concentrations of PMEA in plasma were determined by a highly sensitive method using HPLC analysis with fluorescence detection (24) . Following intravenous bolus injection, PMEA concentrations rapidly declined and fell below the detection limit (0.05 g of PMEA per ml of plasma) within 2 to 3 h after injection (Fig. 3) . The half-life in plasma (calculated from the initial elimination on June 21, 2017 by guest http://aac.asm.org/ phase) was 8.9 min, and the total body clearance was 2.4 liters/kg/h (Table 4) . This is in agreement with our previous data on the pharmacokinetics of intravenous PMEA in mice (26) . In contrast, oral gavage of PMEA resulted in rather low yet sustained concentrations of PMEA in plasma that were detectable up to 8 h after administration (Fig. 3) . Long-lasting appearance of PMEA in the plasma was also observed upon oral gavage of bis(POM)-PMEA. However, in these mice, PMEA reached far higher concentrations in plasma than after oral administration of PMEA [maximum plasma PMEA concentrations, 10.0 and 0.9 g/ml following oral administration of bis(POM)-PMEA and PMEA, respectively]. The oral bioavail- (Table 5 ). Only small amounts of PMEA were recovered in the urine of mice that received oral PMEA or oral diphenyl-PMEA (7.0 and 4.0%, respectively) (dose, 25 mg of PMEA equivalent per kg). Markedly higher urinary recoveries of PMEA were obtained upon oral administration of bis(POM)-PMEA (48.4 and 22.3% at a dose of 25 or 100 mg of PMEA equivalent per kg, respectively).
DISCUSSION
The chronic nature of HIV infection necessitates long-term treatment with antiviral drugs, as is the case with the now commercially available anti-HIV agents, such as zidovudine, zalcitabine, didanosine, and stavudine. For long-term treatment, the compound should be given orally, but for PMEA, oral bioavailability is rather low (7.8% in rats and 4.0% in cynomolgus monkeys) (10, 31) . Recently, a large number of lipophilic esters of PMEA have been synthesized and investigated for their potential as oral prodrugs of PMEA. Bis-(POM)-PMEA and diphenyl-PMEA appeared the most promising, with oral bioavailabilities in rats of 17.6 and 11.1%, respectively (34) . A favorable oral bioavailability for bis-(POM)-PMEA is also suggested by our antiviral data for retrovirus-infected mice. We found that oral bis(POM)-PMEA is highly efficient against MSV and FLV, with an effect identical to that of subcutaneous PMEA given at equimolar dosages (50 or 100 mg/kg/day). Interestingly, short-term (5-day) treatment was sufficient to obtain a marked antiretroviral response. In contrast, PMEA and diphenyl-PMEA had only marginal antiviral activity when given orally.
The antiviral results closely correlated with our pharmacokinetic data for mice. When measuring the concentrations of free PMEA in plasma upon oral administration of equimolar doses of bis(POM)-PMEA, diphenyl-PMEA, or PMEA, we found oral bioavailabilities of PMEA of 53, 3, and 16%, respectively. The oral bioavailabilities obtained by detection of PMEA in the plasma fitted nicely with the data for the urinary recovery of PMEA. However, in the case of oral bis(POM)-PMEA, urinary excretion of PMEA was clearly dose depen- dent, suggesting that the renal excretion of PMEA may be saturated at the higher dose or that oral absorption of bis-(POM)-PMEA may be saturable. Recent studies with rats have indicated an oral bioavailability of PMEA of 17.6% following oral administration of bis(POM)-PMEA at a dose of 30 mg of PMEA equivalent per kg (33) . This somewhat low value may have resulted from saturation of absorption and/or elimination. The same authors reported an oral bioavailability for diphenyl-PMEA of 11.1%, which is somewhat higher than what we found.
The rather low oral bioavailability that we obtained for diphenyl-PMEA may be due to insufficient absorption of the prodrug by the gastrointestinal system and/or incomplete release of the active compound PMEA. Several data argue in favor of the latter hypothesis. Following oral administration of diphenyl-PMEA, the highest concentrations in plasma were found for unchanged diphenyl-PMEA, followed by monophenyl-PMEA and PMEA. Thus, diphenyl-PMEA appears to be relatively resistant to the high esterase activity of the intestine, liver, and plasma. Moreover, the rather low antiviral activity of diphenyl-PMEA in cell culture also points to insufficient cleavage by cellular esterases. In contrast, bis(POM)-PMEA is readily cleaved to PMEA; after oral gavage in mice, no intact bis(POM)-PMEA was detected in plasma, and only minute amounts of mono(POM)-PMEA were measured shortly after administration (data not shown). Similar observations were made for cynomolgus monkeys (9) . Thus, although bis(POM)-PMEA by itself is a more potent antiviral compound than PMEA in vitro (32, 33 ), this will not necessarily be reflected in the in vivo situation, since bis(POM)-PMEA does not appear to reach the target cells in intact form when administered orally. Rather, the most interesting feature of bis(POM)-PMEA is its efficient delivery of PMEA after oral administration. Therefore, it is clear that the antiviral efficacy of oral bis(POM)-PMEA in the MSV-infected mice cannot be ascribed to a direct cytotoxic effect of bis(POM)-PMEA. That PMEA has no direct antitumor effect in the MSV model has been demonstrated previously in delayed-treatment experiments (4).
Another intriguing observation concerns the long-lasting presence of PMEA in plasma following oral administration of bis(POM)-PMEA to mice. In these mice, a clear elimination phase could not be discerned, making it impossible to calculate a half-life in plasma for PMEA. The prolonged presence of PMEA upon oral administration of bis(POM)-PMEA has several implications for the clinical use of this prodrug. (i) First, infrequent dosing with oral bis(POM)-PMEA may be sufficient to obtain a prolonged antiviral efficacy. We have previously shown that infrequent or single-dose treatment with PMEA is markedly efficacious in MSV-infected mice (3, 24) . This observation is related to the long intracellular half-life of the active diphosphorylated metabolite PMEApp (approximately 18 h) (2) . Intracellular accumulation of PMEApp, combined with sustained release of PMEA in plasma during oral treatment with bis(POM)-PMEA, can be expected to endow bis(POM)-PMEA with favorable antiviral efficacy upon infrequent dosing. (ii) Second, when the plasma elimination curves for PMEA following oral administration of bis(POM)-PMEA or intravenous injection of PMEA were compared, marked differences were observed in the elimination rate (slope of the curve) and the maximum concentration of the drug (maximum of the curve). In contrast, AUCs showed only a twofold difference. In our antiviral efficacy studies, oral bis(POM)-PMEA showed the same activity as parenteral PMEA given at equimolar doses. From these findings, it appears that the AUC of PMEA in the plasma may be a more crucial determinant in the antiviral response than the maximum concentration of PMEA in plasma. This has also been observed with PMEDAP, the 2,6-diaminopurine analog of PMEA, which also displays marked antiviral activity upon oral administration in mice. Like oral bis(POM)-PMEA, oral PMEDAP confers low yet sustained levels of the antiviral agent in plasma (28) . That the AUC plays an important role in the antiviral efficacy has also been demonstrated for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro with a cell culture perfusion system (23) . This in vitro system was previously shown to be useful to predict the minimum effective dose of D4T as used in the clinical setting (6) . (iii) Third, it is evident that oral bis(POM)-PMEA undergoes marked first-pass metabolism, which may result in significant accumulation in the liver of free PMEA that is then slowly released in the circulation. PMEA has been shown to be active against duck hepatitis B virus upon intraperitoneal injection in ducklings (17) . An even higher anti-hepatitis B virus activity may be expected for oral bis-(POM)-PMEA, since this treatment modality could lead to much higher concentrations of PMEA in the liver than intraperitoneal injection of PMEA.
Further in vivo experiments should be performed to assess the therapeutic potential of oral bis(POM)-PMEA. These studies should also address the safety of oral bis(POM)-PMEA, since too-great accumulation of PMEA in the liver may contribute to hepatotoxicity. Our preliminary studies with mice showed that oral treatment with bis(POM)-PMEA, at a dose equivalent to 250 mg of PMEA per kg/day given twice daily for 5 days, resulted in 100% lethality, with a mean time of death of 6.0 days. No lethality was observed at the dosage of 100 mg of PMEA equivalent per kg per day. Under the same conditions, subcutaneous PMEA proved 100% safe at dosages of up to 500 mg/kg/day. Also, no lethality was observed upon infrequent administration of subcutaneous PMEA or oral bis-(POM)-PMEA at a dose of 250 mg of PMEA equivalent per kg administered three times per week for 3 weeks. Previously, oral bis(POM)-PMEA has been reported to cause no lethality or organ toxicity in rats when administered at a dose of 0.6, 20, or 60 mg of PMEA equivalent per kg per day for 2 weeks (18) .
The present study is the first report of the in vivo antiviral efficacy of oral bis(POM)-PMEA. The compound was found to exhibit remarkable efficacy against retrovirus (i.e., MSV and FLV) infections in mice. A major complication for the longterm clinical use of PMEA, i.e., low oral bioavailability, has been resolved by using bis(POM)-PMEA, which proved to be an efficient oral prodrug of PMEA. It should be further explored for its therapeutic potential in patients with HIV, hepatitis B virus, and herpesvirus infections (i.e., virus infections that are sensitive to PMEA).
